Druggability & Clinical Context
Druggability
Low
Score: 0.32
Target Class
Signaling Protein
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
4
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
1 Preclinical
Therapeutic Areas:Amyotrophic lateral sclerosis (ALS) Frontotemporal dementia (FTD) Neurodegeneration RNA metabolism disorders Cancer (dysregulated mRNA transport) Stress granule-related pathologies
Druggability Rationale: SYNCRIP presents low druggability (0.30 score) due to challenges inherent to targeting RNA-binding proteins, which typically lack well-defined small-molecule binding pockets compared to kinases or proteases. However, the availability of 4 PDB structures at 2.6 Å resolution and successful development of preclinical tool compounds and antisense approaches provide a foundation for rational drug design targeting the RNA-binding domain.
Mechanism: Small molecule or antisense-based inhibitors would disrupt SYNCRIP's RNA-binding capability, reducing its ability to facilitate mRNA transport and local protein synthesis, potentially modulating disease pathways in neurological disorders or cancers where SYNCRIP dysfunction is implicated.
Drug Pipeline (2 compounds)
1 Preclinical
Known Drugs:Tool compound targeting SYNCRIP RNA binding domain (preclinical) — Research tool for mRNA transport disorders
Antisense oligonucleotide targeting SYNCRIP mRNA (research) — Potential therapeutic for SYNCRIP-related neurological conditions
Structural Data:PDB (4) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:SYNCRIP contains two RNA recognition motifs (RRMs) that form the primary RNA-binding interface; structural data (PDB: 2DGU, 2MXT, 2NBB, 6KOR) reveals modular binding pockets within these RRM domains characterized by conserved aromatic and basic residues that interact with RNA backbone and bases. Allosteric pockets adjacent to the RNA-binding interface may represent more selective small-molecule targeting opportunities than direct RNA-binding site inhibition.
Selectivity & Safety Considerations
Selectivity is a major concern given SYNCRIP's homology to other hnRNP family members (particularly hnRNP D/AUF1); inhibitors must discriminate between RNA-binding domains across this protein family to avoid off-target effects. Antisense approaches may offer superior selectivity by targeting SYNCRIP-specific mRNA sequences rather than the conserved protein domain.